摘要
Abstract
Objective To observe the efficacy of intermittent treatment of bicalutamide combined with goserelin for locally advanced prostate cancer, and to investigate its nursing points. Methods 146 cases with advanced prostate cancer from June 2012 to June 2014 were randomly divided into the control group and the observation group, 73 cases in each group. The control group was given bicalu-tamide(oral, 50 mg / time, qd) combined with goserelin (injection, 3. 6 mg / time, 1 time / 4 weeks) ) continuous treatment; the observation group was given bicalutamide combined with goserelin intermittent treatment; both groups were given the same nursing measures. The changes of serum PSA and f - PSA before treatment and at 1, 6, 12 months after treatment, as well as the improvement of obstructive voiding symptoms and bone metastases of the two groups were observed and recorded. The cost of the treatment in the two groups was statistically recorded, and the adverse reactions during treatment were recorded. Results Compared with before treatment, both groups showed significant improvement, tumor markers in serum PSA and f - PSA values decreased significantly, and there was a significant reduction in the number of symptoms and bladder obstructive voiding and bone metastases( P ﹤ 0. 05), but without statistically signifi-cant difference between the two groups( P ﹥ 0. 05) . The average cost of treatment in the observation group was significantly lower than the control group( P ﹤ 0. 05) . The main adverse reactions occurred in the two groups were sexual dysfunction, fever, etc. The main ad-verse reactions occurred in the observation group was much fewer than the control group( P ﹤ 0. 05) . Conclusion The application of bicalutamide combined with goserelin intermittent treatment for locally advanced prostate cancer has the same efficacy with the continu-ous treatment. With more effective nursing measures, it can alleviate the clinical symptoms. But intermittent treatment can significantly re-duce the patient's medical cost with fewer adverse reactions and higher safety, which is worthy of clinical promotion.关键词
比卡鲁胺/戈舍瑞林/前列腺癌/临床观察/护理干预Key words
bicalutamide/goserelin/prostate cancer/clinical observation/nursing intervention分类
医药卫生
